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DECREASED GASTRIN SECRETION IN PATIENTS W ITH LATE-ONSET 
HYPOGAMMAGLOBULINEMIA
G i j s b e r t  d e n  H a r t o g ,  M . D . ,  J o s  W . M .  v a n  d e r  M e e r ,  M.D., Ph.D., J a n  B.M.J. J a n s e n ,  M . D., Ph.D.,
R a l p h  v a n  F u r t h ,  M.D., Ph.D., a n d  C o r n e l i s  B.H.YV. L a m e rs ,  M.D., Ph .D.
Abstract We undertook this study to determine whether 
patients with late-onset hypogammaglobulinemia, who 
are at very high risk for gastric cancer, have a reduced 
secretion of gastrin after stimulation with food or bombe­
sin, a potent gastrin-releasing stimulus. We compared the 
plasma gastrin responses to bombesin and to a standard 
test meal in 18 patients with late-onset hypogammaglob­
ulinemia with those in patients with X-linked agamma­
globulinemia, early-onset hypogammaglobulinemia, or hy­
pogammaglobulinemia due to lymphoproliferative cancer, 
and in 30 normal control subjects.
Thirteen of 18 patients with late-onset hypogammaglob­
ulinemia (72 percent) had an abnormally low gastrin 
response to bombesin, as compared with none of 21 
patients with other forms of hypogammaglobulinemia
HYPOGAMMAGLOBULINEMIA comprises aheterogeneous group of immunodeficiency dis­
orders. 1,2 O f the congenital forms, X-linked agamma­
globulinemia has been studied the most thoroughly 
and is characterized by an absence of B lymphocytes 
in the bone marrow, peripheral blood, and lymphoid 
tissues.3,1 There are other forms of early-onset hypo­
gammaglobulinemia, but differentiating them from 
isolated forms of X-linked agammaglobulinemia or 
from early manifestations of late-onset hypogamma­
globulinemia is difficult. When primary hypogamma­
globulinemia develops later in life, the diagnosis of 
late-onset hypogammaglobulinemia (also called com­
mon variable immunodeficiency) is clear.J,b In pa-
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(P<0.05). After a test meal, abnormally low gastrin secre­
tion was found in 6 of 14 patients with late-onset hypo­
gammaglobulinemia (43 percent) and in 1 of 18 patients 
with other forms of the disease (6 percent) (P not sig­
nificant).
The plasma gastrin responses to stimulation with bom­
besin or food distinguished late-onset hypogammaglobu­
linemia from other forms, with sensitivities of 72 and 43 
percent and specificities of 100 and 94 percent, respec­
tively. Stimulated gastrin response can therefore be used 
as a marker for this type of immunodeficiency. The test 
responses also showed heterogeneity among patients 
with late-onset hypogammaglobulinemia and may help to 
identify patients with an increased risk for gastric cancer. 
(N Engl J Med 1988; 318:1563-7.)
tients with late-onset hypogammaglobulinemia, B 
lymphocytes are usually present, but they do not dif­
ferentiate into plasma cells/ This humoral immuno­
deficiency is often accompanied by abnormalities in 
the T lymphocytes. The disease has been classified as 
a combined immunodeficiency disorder by the World
J  4
Health Organization.(> The cellular immune defects 
accompanying late-onset hypogammaglobulinemia 
are by no means constant or homogeneous, and it re­
mains uncertain whether late-onset hypogammaglob­
ulinemia represents a single entity.7' 10 Low serum 
concentrations of gammaglobulin can occur not only 
in primary forms of hypogammaglobulinemia but also 
in hematologic cancer or intestinal or renal disease (as 
a result of loss of protein) . 11
In addition to an increased susceptibility to infec­
tion, patients with primary hypogammaglobulinemia 
often have abnormalities of the gastrointestinal tract, 
including malabsorption, lymphonodular small-intes­
tinal hyperplasia, pernicious anemia, and gastric can- 
cer 5,12-23 These gastrointestinal disorders have been
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reported mainly in patients with late-onset hypogam- 
maglobulinemia,D’l4’24’2:> but recent studies indicate 
that patients with other types of hypogammaglobulin­
emia may also have such abnormalities. 15?26 Patients 
with late-onset hypogammaglobulinemia have a 50- 
fold increase in the incidence of stomach cancer.2' 
Patients with the intestinal type of gastric cancer have 
a reduced plasma gastrin response to the gastrin- 
releasing peptide bombesin.28 We therefore studied 
plasma gastrin secretion during bombesin infusion in 
patients with various forms of hypogammaglobuline­
mia to determine whether such patients have abnor­
malities in gastrin secretion after stimulation and 
whether those abnormalities are speciiic to subgroups 
of patients with hypogammaglobulinemia. Since bom­
besin is not readily available, we also measured post­
prandial plasma gastrin levels to determine whether 
bombesin can be replaced by a meal as a stimulant of 
gastrin secretion.
M e t h o d s
Patients
T h e  s tu d y  w as  perform ed in a g r o u p  o f  33 patients w ith  p r im a r y  
h y p o g a m m a g lo b u l i n e m i a ,  consist ing  o f  10 m ale  patients w ith  X -  
linkcd h y p o g a m m a g lo b u l i n e m i a  (m ean age,  23 years;  range,  14 to 
35), 5 patients (4 m a le  and  1 fem ale  patient) with early-onset  h y p o ­
g a m m a g l o b u l in e m ia  (m ean  age, 22 years;  range,  17 to 25), a n d  18 
patients (13 m en and 5 w o m e n )  with late-onset h y p o g a m m a g l o b u ­
linem ia (m ean age,  42 years;  range,  21 to 67). W e  also studied six 
patients  (five men and  one w o m a n ;  40 to 70 years  o f  age) with 
h y p o g a m m a g lo b u l i n e m i a  d u e  to ly m p h o p ro l i fe ra t iv e  c a n c e r —  tw o 
with ch ro n ic  ly m p h o c y t ic  leukem ia ,  one w ith  n o n - H o d g k in ’s l y m ­
p h o m a ,  and  three with m ult ip le  m y e lo m a .  T h i r t y  norm al subjects  
(24 men and  6 w o m e n ;  m ean age,  43 years;  range,  24 to 72) with  
neither im m u n o d e f ic ie n c y  nor recurrent  infection served as con-
4
trols. Before treatm ent,  all patients  with h y p o g a m m a g lo b u l in e m ia  
excep t  one had m a rk e d ly  redu ced  seru m  g a m m a g lo b u l in  c o n c e n tra ­
tions (range,  0 to 4.5 g  per  liter). O n e  patient  w ith  a g a m m a g lo b u l in  
co n cen tra t io n  o f  6.0 g  per liter, a m e m b e r  o f  a family  with X - l in k e d  
a g a m m a g l o b u l in e m ia ,  had  no I g A ,  I g M ,  I g G 2, or  I g G 4 , but had 
n early  norm al  co n cen tra t io n s  o f  I g G l  and  I g G 3 —  a f inding that 
has been reported e ls e w h e re .29
Inform ed consent  w a s  o b ta in e d  from all subjects ,  and  the proto­
col w as  a p p r o v e d  by the ethics c o m m itte e  o f  the U n iv e rs i ty  H o s p i­
tal o f  L e id e n .
Criteria
T h e  criteria  for the d iagnosis  o f  X - l in k c d  a g a m m a g lo b u l in e m ia  
w ere  the onset o f  c l inical  signs d u r in g  the first two years  o f  life, a 
fam ily  history c o m p a t ib le  with an X - l in k ed  pattern  o f  inheritance,  
and  an a b se n c e  o f  or profound d ecrea se  in B ly m p h o c y te s  in the 
periphera l  blood or bone m a rro w .  In patients in w h o m  clinical  
s y m p t o m s  b egan  before the a g e  o f  tw o years  but no ev id en ce  for 
X - l in k e d  in h er itan ce  w as  found, the d iagnosis  o f  early-onset  h y p o ­
g a m m a g l o b u l i n e m i a  w as  m ade.  In these patients,  B ly m p h o c y te s  
w ere  e ither  absen t ,  scarce,  or present in norm al n um bers .  Patients  
w e r e  considered  to h ave  late-onset h y p o g a m m a g lo b u l i n e m i a  if  
c l inical  m anifestat ions  began  after the age  o f  10 years  and B ly m ­
ph ocytes ,  but not p la s m a  cells, w ere  found in the bone m arro w .
Bombesin-lnfusion and Food Stimulation of Gastrin 
Secretion
Patients  w e re  studied  after they had fasted overnigh t .  P la s m a  
gastr in  levels after s t im ulat ion  w ith  b o m b e sin  w ere  m e a su re d  in all 
subjects ,  w h e re a s  gastr in  levels after s t im u lat io n  w ith  food w ere
m easured  in all 10 patients w ith  X - l in k c d  a g a m m a g lo b u l in e m ia ,  in
14 o f  the 18 patients  with  late-onset h y p o g a m m a g lo b u l in e m ia ,  in 4 
o f  the 5 patients  w ith  the early-onset  form, in 4 o f  the 6 patients  w ith  
h y p o g a m m a g lo b u l i n e m i a  d u e  to lym p h o p ro l i fe ra t iv e  cancer,  and in 
all 30 control  subjects .  S y n th e t ic  b o m b e s in-14 ( U C B ,  Brussels) w as  
infused in tra v e n o u s ly  (60 pm ol per k i lo gram  o f  b o d y  w eigh t  for 20 
m inutes) .  Ja,30‘31 Blood sam ples  for m ea su rem en ts  o f  gastrin  w ere  
o b ta in e d  at —5 , 0 , 5 , 10, 15, and 20 m inutes.  T h e  s tan d ard  test meal 
consisted o f  o n e  slice o f  bread ,  50 g  o f  cheese,  15 g  o f  m argarin e ,  
one boiled egg,  and 200 ml o f  skim milk. S eru m  gastrin  w as  m e a s ­
ured at 15-m in u te  intervals  for 120 m inutes.  P la sm a  gastrin  levels 
w ere  assessed b y  r a d io im m u n o a s s a y .30,31
Statistical Analysis
A  m ea n  basal  p la s m a  co n cen tra t io n  o f  gastr in  w as  ca lcu lated .  
T h e  integrated  p lasm a  gastr in  secretion w as  d eterm in ed  by c a lc u ­
lat ing  the area  un d er  the time cu rve  for p la s m a  concen trat ion ,  after 
basal  va lu es  had been su b tracted .  T o  ca lc u la te  the increm enta l  
va lu e ,  the m ean basal  level w as  su b tracte d  from the peak p lasm a  
gastr in  co n cen trat io n  d u r in g  st im ulat ion .  Statist ical  analysis  w as  
perform ed w ith  use o f  the ch i-sq u a re  test w ith  Y a t e s ’ correction and 
S p e a r m a n ’s correlat ion test.
R e s u l t s
In the normal subjects, plasma concentrations of 
gastrin ranged from 10 to 40 pmol per liter. A reduced 
basal plasma concentration of gastrin after bombesin 
stimulation was observed in 6 of the 18 patients (33 
percent) with late-onset hypogammaglobulinemia as 
compared with none of the 21 patients with the other 
forms of hypogammaglobulinemia (P<0.05). Both 
bombesin and food increased plasma gastrin levels in 
all groups of subjects studied (Fig. 1 and 2). A reduc­
tion in integrated plasma gastrin secretion in response 
to bombesin was observed in 13 of the 18 patients (72 
percent) with late-onset hypogammaglobulinemia, as 
compared with none of the 21 patients with other 
forms of hypogammaglobulinemia (P<0.05; Fig. 1), 
whereas a reduced postprandial level of plasma gas­
trin secretion was found in 6 of the 14 (43 percent) 
and 1 of the 18 patients (6 percent) with late-onset 
and other forms of hypogammaglobulinemia, respec­
tively (P not significant; Fig. 2). The incremental 
plasma gastrin secretion in the patients with late-onset 
hypogammaglobulinemia was reduced in 13 of the 
18 patients who received bombesin (72 percent) and 
in 4 of the 14 who were given food (29 percent), 
as compared with none of the 21 and 18 patients 
with other forms of hypogammaglobulinemia who 
received bombesin (P<0.05) and food (P not signifi­
cant), respectively.
The low levels of plasma gastrin secretion in the 
patients with late-onset hypogammaglobulinemia 
were not correlated with age (r = 0.19), sex, or dura­
tion of illness (r = 0.12).
D i s c u s s i o n
We found a reduced gastrin response to the infusion 
of bombesin or the ingestion of food in 33 and 22 
percent, respectively, of patients with hypogamma­
globulinemia. Interestingly, these abnormalities were 
restricted to patients with late-onset hypogammaglob-
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Figure 1. Integrated Plasma Gastrin Secretion during the Infusion
of Bombesin.
Bombesin was given to 30 normal subjects, 18 patients with late- 
onset hypogammaglobulinemia, and 21 patients with other forms 
of hypogammaglobulinemia: 10 with X-linked agammaglobuline­
mia (crosses), 5 with early-onset hypogammaglobulinemia (solid 
circles), and 6 with secondary hypogammaglobulinemia (trian­
gles). pM-20min denotes picomoles per liter per 20 minutes.
ulinemia; none of the 21 patients with other forms of 
hypogammaglobulinemia had reduced plasma gastrin 
secretion. A reduced integrated plasma gastrin re­
sponse but a normal incremental response to stimula­
tion with food was observed in only 1 of the 18 patients 
with the other forms of hypogammaglobulinemia. 
Among the patients with late-onset hypogammaglob­
ulinemia, 72 percent had an abnormally low gastrin 
response to bombesin, and 43 percent had a reduced 
response to food. Thus, the plasma gastrin response to 
bombesin distinguished late-onset hypogammaglobu­
linemia from the other forms, with a sensitivity of 72 
percent and a specificity of 100 percent. This discrimi­
nation was better than that obtained with the food- 
stimulation test, which yielded a sensitivity of 43 per­
cent and a specificity of 94 percent. Since there was no 
correlation between a low plasma gastrin response 
and the age of the patient, or the duration of clinical 
symptoms, it is unlikely that such a response is merely
a late manifestation of any type of hypogammaglobu­
linemia. Furthermore, gastrin responses were normal 
in the 10 patients with X-linked agammaglobuline­
mia, whose ages overlapped with those of patients 
with the late-onset form.
Our findings may have clinical importance. The 
stimulation test may help in the classification of cases 
of primary hypogammaglobulinemia. Although var­
ious immunologic markers are available, such classi­
fication is difficult in certain patients. 1’2’6 Also, the test 
may aid in the differentiation of primary hypogam­
maglobulinemia from hypogammaglobulinemia due 
to chronic lymphocytic leukemia and other lympho­
proliferative cancers. 11 We do not know whether, 
among patients with late-onset hypogammaglobuline­
mia, those with and without an abnormal gastrin 
response represent separate disease entities; this 
must be determined in large comparative studies.
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Figure 2. Integrated Plasma Gastrin Secretion after Stimulation
with Food.
A test meal was given to 30 normal subjects, 14 patients with late- 
onset hypogammaglobulinemia, and 18 patients with other forms 
of hypogammaglobulinemia: 10 with X-linked agammaglobuline­
mia (crosses), 4 with early-onset hypogammaglobulinemia (cir­
cles), and 4 with secondary hypogammaglobulinemia (triangles). 
pM-120min denotes picomoles per liter per 120 minutes.
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We observed no obvious clinical or biochemical dif­
ferences between the two groups.
The test may also provide a noninvasive way to 
identify patients with hypogammaglobulinemia who 
are at risk for gastric cancer. It has been shown that 
among patients with late-onset hypogammaglobuline­
mia, there is a 50-fold increase in the incidence of 
gastric cancer2/; such an elevation has not been ob­
served among patients with other types of hypogam­
maglobulinemia. In fact, patients with late-onset hy­
pogammaglobulinemia have the highest known risk of 
gastric cancer. Therefore, a low plasma gastrin re­
sponse to bombesin or food may serve as a marker in 
the selection of patients for prospective gastroscopic 
evaluation. Since a low plasma gastrin response to 
bombesin has been found in patients with gastric can­
cer but normal serum gammaglobulin levels,28 it is 
tempting to hypothesize that the development of gas­
tric cancer is restricted to patients with abnormal gas­
trin secretion. Prospective studies are needed to sup­
port or reject this hypothesis, however.
The mechanism of the low plasma gastrin response 
to bombesin and food is unknown. Bombesin, a neuro­
peptide, is involved in the vagal stimulation of gastrin 
release from the gastric antrum. ' 2 The infusion of 
bombesin is a potent stimulus of gastrin secretion in 
several species of animals and in humans.30,31,33 Un­
like food, which stimulates gastrin release from both 
the antrum and the duodenum, bombesin mainly
J
stimulates the antral G cells.31 The normal postpran­
dial secretion of plasma gastrin in some patients with 
late-onset hypogammaglobulinemia, despite a re­
duced response to bombesin, may be caused by release 
of gastrin from the duodenum after stimulation with 
food. It is not known whether the abnormally low gas­
trin response is due to a reduced sensitivity of antral G 
cells to stimulation with bombesin or food, or a reduc­
tion in the number of G cells. It should be noted that 
none of our patients had abnormal gastric symptoms. 
Low basal plasma concentrations of gastrin have pre­
viously been reported in patients with pernicious 
anemia associated with hypogammaglobulinemia, 18 
whereas elevated gastrin levels are usually observed in 
patients with pernicious anemia who have normal 
concentrations of serum gammaglobulin.35,30 In the 
present study, abnormally low plasma gastrin secre­
tion was not restricted to patients with pernicious ane­
mia (3 of the 18 patients studied).
We have shown that, in contrast to patients with 
other types of hypogammaglobulinemia, the majority 
of patients with late-onset hypogammaglobulinemia 
have a reduced plasma gastrin response to food or 
bombesin. Plasma gastrin secretion can therefore be 
used as a marker of this type of immunodeficiency. 
Since bombesin is not readily available, stimulation 
with food may be the preferred initial diagnostic pro­
cedure, although the sensitivity of the test of post­
prandial gastrin secretion is somewhat lower than that 
of the test using bombesin. Both tests indicate hetero­
geneity among patients with late-onset hypogamma­
globulinemia and may help to identify those with an 
increased risk of gastric cancer.
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CLINICAL IMPORTANCE OF NEAR-DIPLOID TUMOR STEM LINES IN PATIENTS 
WITH OSTEOSARCOMA OF AN EXTREMITY
A. T h o m a s  L o o k , M.D., E d w i n  C. D o u g l a s s , M.D., a n d  W i l l i a m  H. M e y e r , M.D.
Abstract We determined the clinical value of flow- 
cytometric measurement of tumor-cell DNA content, which 
reflects the chromosome number (ploidy), in patients with 
osteosarcoma of an extremity. Hyperdiploid stem lines 
were identified in 25 of 26 tumor samples obtained at 
diagnosis from patients who did not have clinically overt 
metastases. Near-diploid tumor stem lines coexisted with 
hyperdiploid lines in 15 of these 25 cases; an isolated 
near-diploid line was present in the 26th case. All 26 
patients underwent definitive surgery and then were 
treated uniformly with intensive adjuvant combination 
chemotherapy.
Kaplan-Meier analysis of both relapse-free and overall 
survival times showed that the presence of a near-diploid 
tumor stem line was associated with improved outcome 
(P = 0.003 for each comparison). After a median follow- 
up time of three years, pulmonary metastases developed
in only 2 patients in the group with near-diploid lines, 
in contrast to 7 of the 10 with hyperdiploid lines exclu­
sively. Near diploidy remained significantly associated 
with improved relapse-free survival after adjustment for 
the influence of age, the only clinical variable that 
showed prognostic strength in this analysis (P<0.01; rel­
ative risk, 0.08; 95 percent confidence interval, 0.02 
to 0.48).
Our findings demonstrate the usefulness of flow-cyto- 
metric determination of tumor-cell ploidy for predicting 
the sensitivity of histologically high-grade osteosarcoma 
to chemotherapeutic agents. Patients with a near-diploid 
tumor stem line can be expected to respond favorably 
to adjuvant chemotherapy as used in this study, where­
as those with only hyperdiploid lines should be consid­
ered as candidates for alternative therapy. (N Engl J Med 
1988; 318:1567-72.)
OSTEOSARCOMA is a rapidly metastasizing bone tumor that poses difficult challenges to the 
therapist. Early development of pulmonary metasta­
ses in most patients who have undergone amputation 
but not adjuvant chemotherapy indicates that clini­
cally inapparent tumor cells are usually present in 
the lungs at the time of diagnosis. Recently, two 
groups of investigators established in controlled 
clinical trials that multiagent chemotherapy adminis­
tered after definitive surgery improves the relapse-free 
survival of patients with high-grade osteosarcoma. 1,2 
However, in those studies and in others,3' 12 metas­
tases eventually appeared in approximately one third 
to one half of all patients who received adjuvant 
treatment.
A major obstacle to the development of uniformly 
effective adjuvant chemotherapy for osteosarcoma has
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been the lack of understanding of the biologic factors 
that determine the sensitivity of a particular tumor to 
drugs. 13 As a first step toward identifying clinically 
useful prognostic markers in this disease, we measured 
the DNA content of tumor cells collected before treat­
ment in patients who had been enrolled in the multi- 
institutional study of Link et al. 1 This approach was 
attractive because measurement of cellular DNA con­
tent according to flow-cytometric techniques provides 
reliable estimates of the chromosome number (ploidy) 
in malignant stem lines and correlates well with the 
response to chemotherapy in childhood acute lympho­
blastic leukemia, 14 neuroblastoma of infants, 15 and 
Wilms' tumor. 10 Hiddemann et al.1' have shown that 
measurement of DNA in patients with osteosarcoma 
can distinguish between hyperdiploid tumors with 
highly malignant features and tumors classified as 
parosteal variants, which have diploid DNA stem 
lines, well-differentiated histologic features, and a rel­
atively favorable prognosis.
The results of our investigation indicate that histo­
logically high-grade osteosarcomas with near-diploid 
stem lines respond significantly better to adjuvant 
combination chemotherapy than do tumors with only 
hyperdiploid lines. Patients whose tumors do not have
